Survival Benefit of Stereotactic Radiosurgery for Patients with Malignant Glial Neoplasms
The DOI matches its Crossref record; 1 of the 1 references it cites were found in a registry or an index.
Abstract
OBJECTIVE: During an 8-year interval, we evaluated the survival benefit of stereotactic radiosurgery performed in 64 patients with glioblastomas multiforme (GBM) and 43 patients with anaplastic astrocytomas (AA). METHODS: Adjuvant radiosurgery was performed either before disease progression or for recurrent tumor at the time of disease progression. Clinical and imaging follow-up data were obtained for all patients. The diagnosis of GBM was obtained by performing craniotomies in 41 patients and by performing stereotactic biopsies in 23. The diagnosis of AA was obtained by performing craniotomies in 19 patients (44%) and by performing biopsies in 24. RESULTS: Of the entire series, the median survival time after initial diagnosis for patients with GBM was 26 months (standard deviation [SD], 19 mo; range, 5-79 mo) and the median survival time after radiosurgery was 16 months (SD, 16 mo; range, 1-74 mo). The 2-year survival rate was 51%. No survival benefit was identified for patients who underwent intravenously administered chemotherapy in addition to radiosurgery (P = 0.97). After undergoing radiosurgery, 12 patients (19%) underwent craniotomies and resections and 4 (6%) underwent subsequent radiosurgery for regional or remote recurrence. For 45 patients who underwent radiosurgery as part of the initial management plan, the median survival time after diagnosis was 20 months. Of the entire series, the median survival time after diagnosis for patients with anaplastic astrocytomas was 32 months (SD, 23 mo; range 5-96 mo) and the median survival time after radiosurgery was 21 months (SD, 18 mo; range 3-93 mo). The 2-year survival rate was 67%. Ten patients (23%) underwent subsequent craniotomies at a mean of 8 months after initial surgery, and two underwent subsequent radiosurgery. There was no acute neurological morbidity after radiosurgery. Histologically proven radiation necrosis occurred in one patient with GBM (1.6%) and two patients with AA (4.7%). For 21 patients for whom radiosurgery was part of the initial management plan, the median survival time after diagnosis was 56 months. CONCLUSION: In comparison to historical controls, improved survival benefit after radiosurgery was identified for patients with GBM and patients with AA. Although this survival benefit may be related to our selection of patients for radiosurgery based on their having smaller tumor volumes, no selection was made based on location. We observed that radiosurgery was safe and well tolerated. Its effectiveness as an adjuvant therapy deserves a properly stratified randomized trial.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
A Confidence Interval for the Median Survival Time
Brookmeyer, R., & Crowley, J. (1982) · Biometrics · doi:10.2307/2530286 · Cited by 914
Cited by
Radiotherapy for newly diagnosed malignant glioma in adults: a systematic review
Laperriere, N., Zuraw, L., & Cairncross, G. (2002) · Radiotherapy and Oncology · doi:10.1016/s0167-8140(02)00078-6 · Cited by 424
Debulking or biopsy of malignant glioma in elderly people – a randomised study
Vuorinen, V., Hinkka, S., Färkkilä, M., & Jääskeläinen, J. (2003) · Acta Neurochirurgica · doi:10.1007/s00701-002-1030-6 · Cited by 370
Clinical outcomes after stereotactic radiosurgery for idiopathic trigeminal neuralgia
Maesawa, S., Salame, C., Flickinger, J. C., Pirris, S., Kondziolka, D., & Lunsford, L. D. (2001) · Journal of Neurosurgery · doi:10.3171/jns.2001.94.1.0014 · Cited by 329
Self-citation
Metadata
- Authors
- Kondziolka, D., Flickinger, J. C., Bissonette, D. J., Bozik, M., & Lunsford, L. D.
- Venue
- Neurosurgery
- Published
- 1997-10-01
- Volume
- 41
- Issue
- 4
- Pages
- 776-785
- ISSN
- 0148-396X (ISSN-L)
- 1524-4040
- OpenAlex
- W1989837095
- Cited by
- 224
- References
- 1
- FWCI
- 7.13
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Survival Benefit of Stereotactic Radiosurgery for Patients with Malignant Glial Neoplasms. https://app.cochat.ai/papers/10.1097/00006123-199710000-00004
- The paper
- Kondziolka, D., Flickinger, J. C., Bissonette, D. J., Bozik, M., & Lunsford, L. D. (1997). Survival Benefit of Stereotactic Radiosurgery for Patients with Malignant Glial Neoplasms. Neurosurgery. https://doi.org/10.1097/00006123-199710000-00004
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.